01—Abstract
Summary
Summary of the 10-K/A filed January 8, 2025. Cited figures are marked; the original filing is the authoritative source.
This filing is Amendment No. 1 (Form 10-K/A) to BeiGene, Ltd.'s (now BeOne Medicines, NASDAQ: ONC) annual report for fiscal year 2023, filed January 8, 2025.
It does not contain the full consolidated financial statements, revenue, or segment data. It was filed to add parent-company-only condensed financial information (Schedule I, Rule 5-04 of Regulation S-X), which the company required because restricted net assets of its consolidated subsidiaries exceeded 25%a of consolidated net assets at year-end 2023 and 2022. Investors should read it alongside the original 10-K filed February 26, 2024.
The parent-only figures show a company whose holding-company liquidity has tightened. Parent net loss narrowed to $881.7 millionb in 2023 from $2,003.8 million in 2022, but parent cash and equivalents fell to $724.0 million from $1,742.3 million. Parent operating cash outflow was $1,168.6 million, up from $882.1 million, and was funded partly by $547.2 million of short-term bank debt, up from $297.9 million.
Parent shareholders' equity declined to $3,537.3 millionc from $4,383.4 million. Investments in wholly owned subsidiaries rose to $1,207.4 million from $229.6 million, reflecting $883.3 million of capital injected into subsidiaries during 2023. The filing also discloses a $8.85 million remaining capital commitment on an equity investment and an unconditional parent guarantee of obligations of BeiGene Switzerland GmbH under the global strategic oncology collaboration with Amgen, with no amounts recognized.
The auditors are Ernst & Young LLP and Ernst & Young Hua Ming LLP, both with reports dated January 8, 2025. The cover page also checks the box for error corrections in the financial statements, though this amendment does not explain the nature of those corrections. Non-affiliate market value was about $10.5 billiond as of June 30, 2023.
02—Key points
Key Highlights
- Filing type: Amendment No. 1 (10-K/A) to the FY2023 Form 10-K, filed January 8, 2025, solely to add parent-company-only financial statements under Rule 5-04 of Regulation S-X; it contains no consolidated financial statements.
- Parent-only net loss narrowed to $881.7 million in 2023 from $2,003.8 million in 2022 and $1,457.8 million in 2021, driven largely by lower other expense and lower R&D expense at the parent level ($326.6 million vs. $637.2 million).
- Parent liquidity declined: cash and equivalents fell to $724.0 million from $1,742.3 million, and net cash used in operating activities widened to $1,168.6 million from $882.1 million.
- Parent short-term debt rose to $547.2 million from $297.9 million, with total parent liabilities of $1,279.1 million; the company relies on floating-rate bank lines, including SOFR-linked and RMB-denominated facilities at 2.0% to 7.3%.
- Parent shareholders' equity fell to $3,537.3 million from $4,383.4 million, while investments in wholly owned subsidiaries increased to $1,207.4 million from $229.6 million after $883.3 million of capital injected into subsidiaries.
- Disclosed contingencies are minor: an $8.85 million remaining capital commitment on an equity investment and a parent guarantee of BeiGene Switzerland GmbH obligations under the Amgen collaboration, with no amounts recognized.
- Cover page flags error corrections to previously issued financials and states that no incentive-compensation recovery analysis was required; the amendment itself does not describe the nature or magnitude of the corrections.
03—One dollar
Follow one dollar
For each $1.00 of revenue in FY2023, BeOne Medicines Ltd. lost $0.36.
- Revenue$2.46B100.0%
- Cost of revenue−$379.9M15.5%
- Gross profit$2.08B84.5%
- Operating costs−$3.29B133.7%
- Operating income−$1.21B49.1%
- Interest, other & tax$326.0M13.3%
- Net income−$881.7M35.9%
04—Financials
Financial Highlights
Figures from 10-K/AFY2023filed January 8, 2025Financial Statements
FY2023 against FY2022
| Line item | FY2023FY2022 | Change |
|---|---|---|
| Revenue | $2.46B$1.42B | +73.7% |
| Gross Profit | $2.08B$1.13B | +84.1% |
| R&D Expenses | $1.78B$1.64B | +8.4% |
| SG&A Expenses | $1.51B$1.28B | +17.9% |
| Operating Expenses | $3.29B$2.92B | +12.6% |
| Operating Income | -$1.21B-$1.79B | +32.5% |
| Interest Expense | $20.80M$21.70M | −4.1% |
| Net Income | -$881.71M-$2.00B | +56.0% |
| EPS (Basic) | $-0.65$-1.49 | +56.4% |
| EPS (Diluted) | $-0.65$-1.49 | +56.4% |
| Shares Outstanding (Basic) | 1.36B1.34B | +1.2% |
| Shares Outstanding (Diluted) | 1.36B1.34B | +1.2% |
05—Questions
Frequently Asked Questions
Why was this 10-K/A filed, and does it change the company's reported results?
It was filed to comply with Rule 5-04 of Regulation S-X, which requires parent-company-only condensed financial statements when restricted net assets of consolidated subsidiaries exceed 25% of consolidated net assets. The company met that threshold for FY2023 and FY2022. The amendment states that it does not modify other information in the original 10-K and does not reflect later events, so it does not change consolidated results.
What do the parent-only statements tell investors about the company's cash position?
The parent entity's cash fell by about $1.02 billion in 2023 to $724.0 million, with $1,168.6 million of operating cash outflow and $883.3 million invested in subsidiaries. Financing was partly offset by $547.8 million of new short-term loans, so the parent's liquidity depends increasingly on short-term bank borrowing. Because parent-only figures exclude the operating subsidiaries' cash, they should be read alongside consolidated liquidity in the original 10-K.
Are there material guarantees or commitments that could create future cash obligations?
The disclosed items are limited. The parent has a remaining capital commitment of $8.85 million on an equity investment, to be paid over the investment period, and has unconditionally guaranteed payment and performance of obligations of BeiGene Switzerland GmbH under the Amgen collaboration. No liability has been recognized for the guarantee. The parent states it has no other material contingencies, long-term obligations, or guarantees beyond those in the consolidated statements.
Does the filing explain the error corrections flagged on the cover page?
Not in detail. The cover page checks the box indicating that financial statements reflect correction of an error to previously issued financial statements, and the auditor's report on 2021 references a correction of error dated February 27, 2023. The amendment does not describe the nature, amount, or affected periods of the corrections, so investors should review the original 10-K and related filings for those details.
06—Continue